Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (NEFERTT)
This study is ongoing, but not recruiting participants.
Study NCT00915018 Information provided by Puma Biotechnology, Inc.
First Received on June 4, 2009. Last Updated on November 12, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Breast Cancer
Additional conditions recognized in this trial
More general conditions related to this trial
Neoplasms by Site
Interventions listed in this trial
Neratinib + Paclitaxel
Trastuzumab + Paclitaxel
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action
Sponsors listed in this trial
Puma Biotechnology, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers